Centrexion Therapeutics is a biopharmaceutical product development company seeking to develop a new class of therapeutics that stops pain at its source. Its non-opioid clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Centrexion’s pipeline targets major unmet needs in the treatment of severe pain caused by human and canine osteoarthritis, nerve injury, and herpes zoster viral infection.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer and infectious disease. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.